Physician profile
Thomas E Clinch
NPI 1437186350
$104,152.29
in general payments reported to CMS, 2019-2025
23 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78K · 2020: $7,919 · 2021: $12K · 2022: $4,209 · 2023: $573 · 2024: $1,680 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576 · Travel and Lodging: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.34 |
| Travel and Lodging | $888.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $95,411.10 | 2019-2024 | Tecnis Simplicity, Tecnis Iol, Catalys System |
| Shire North American Group INC | $4,312.68 | 2019 | |
| Alcon Vision LLC | $2,671.31 | 2019-2024 | Clareon |
| Novartis Pharmaceuticals Corporation | $373.49 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $283.25 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $150.41 | 2023-2024 | Tyrvaya |
| Rxsight INC | $145.53 | 2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $106.60 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $85.45 | 2023 | Vyzulta, Miebo |
| Dompe US, INC. | $81.00 | 2020-2025 | Oxervate |
| Glaukos Corporation | $80.99 | 2019-2023 | |
| Allergan, INC. | $79.34 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $71.51 | 2025 | Xdemvy |
| Abbvie INC. | $68.55 | 2023-2024 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $66.16 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $50.67 | 2024-2025 | Vevye |
| Amgen INC. | $26.99 | 2025 | Tepezza |
| Omeros Corporation | $24.25 | 2019-2020 | |
| Horizon Therapeutics Plc | $22.43 | 2023 | Tepezza |
| Biotissue Holdings INC. | $21.18 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$210,060.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Clinch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.